Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2018 Earnings Presentation
19 slides from Novo Nordisk A/s Class B's earnings presentation, May 2, 2018
Slide 1: First three months of 2018 Conference call
Slide 1 First three months of 2018 Conference call Manato Shirley Ohara, diagnosed Adelia Stewart with has type type 1 diabetes 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
Slide 2: Agenda
Conference call First three months of 2018 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
Slide 3: Forward-looking statements
Conference call First three months of 2018 Slide 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company’s statutory Annual Report 2017 and Form 20-F, which are both filed with
Slide 4: Highlights – First three months of 2018
Conference call First three months of 2018 Slide 4 Highlights – First three months of 2018 Sales development • Sales decreased by 5% in Danish kroner and increased by 5% in local currencies to DKK 26.9 billion • International Operations sales were flat in Danish kroner and grew by 8% in local curren
Slide 5: Sales growth driven by both International Operations and North America Operations
Conference call First three months of 2018 Slide 5 Sales growth driven by both International Operations and North America Operations Sales as reported – first quarter of 2018 Growth break down – first quarter of 2018 Region Region Latin America Local currencies Growth Share of growth Japan & Korea +
Slide 6: Sales growth in local currencies of 5% mainly driven by Victoza and Saxenda
Conference call First three months of 2018 Slide 6 Sales growth in local currencies of 5% mainly driven by Victoza® and Saxenda® Sales as reported – first quarter of 2018 Growth break down – first quarter of 2018 Growth Other Local currencies Growth Share of growth hormone biopharmaceuticals Long-ac
Slide 7: Novo Nordisk aims for leadership in long-acting insulin and sustained leadership for fast-acting and premix insulin
Conference call First three months of 2018 Slide 7 Novo Nordisk aims for leadership in long-acting insulin and sustained leadership for fast-acting and premix insulin Long-acting insulin1 volume Fast-acting insulin2 volume Premix insulin3 volume market market share across regions market share across
Slide 8: Novo Nordisk holds ~35% volume market share of the basal market in the USA
Conference call First three months of 2018 Slide 8 Novo Nordisk holds ~35% volume market share of the basal market in the USA Weekly TRx volume market shares1 in the USA Tresiba® launch in the USA glargine U100 NN Total Basal Levemir® • Tresiba® TRx volume market share is now 11.8% Basal volume Tres
Slide 9: Victoza sales growth of 20% in the USA driven by GLP-1 market volume growth
Conference call First three months of 2018 Slide 9 Victoza® sales growth of 20% in the USA driven by GLP-1 market volume growth of ~23% USA GLP-1 market development USA GLP-1 market monthly TRx USA GLP-1 volume market share MAT GLP-1 Total TRx Growth rate GLP-1 TRx NN GLP-1 dulaglutide GLP-1 TRx NN
Slide 10: First phase 3a trial with oral semaglutide, PIONEER 1, completed
Conference call First three months of 2018 Slide 10 First phase 3a trial with oral semaglutide, PIONEER 1, in adults with type 2 diabetes completed Reduction in HbA1c with oral semaglutide, Reduction in body weight with oral semaglutide, administered once daily as a tablet vs placebo administered on
Slide 11: All PIONEER trials for oral semaglutide expected to read-out during 2018
Conference call First three months of 2018 Slide 11 All 10 PIONEER trials for oral semaglutide expected to read-out during 2018 2016 2017 Q1 20181 Q2 20181 Q3 20181 Q4 20181 PIONEER 1: monotherapy2 26 weeks, n=704 PIONEER 2: vs empagliflozin2 52 weeks, n=816 PIONEER 3: vs sitagliptin2 78 weeks, n=1,
Slide 12: Tresiba label in the USA updated based on DEVOTE trial data
Conference call First three months of 2018 Slide 12 Tresiba® label in the USA updated based on DEVOTE trial data Lower rates of severe hypoglycaemia FDA approved a label update for Tresiba® for demonstrated in DEVOTE trial people with type 2 diabetes glargine U100 Tresiba® • Food and Drug Administra
Slide 13: Key development milestones
Conference call First three months of 2018 Slide 13 Key development milestones • Ozempic® granted marketing authorisation by European Commission and approved in Japan • Variation applications for Ozempic® submitted to the EMA for the devices and inclusion of SUSTAIN 7 data • New drug application for
Slide 14: R&D milestones in 2018
Conference call First three months of 2018 Slide 14 R&D milestones in 2018 Results available1 Regulatory milestone Project Q1 2018 Q2 2018 Q3 2018 Q4 2018 DEVOTE and SWITCH2 Tresiba® US regulatory decision DUAL I Japan Phase 3a Xultophy® Japan submission DUAL II Japan Phase 3a Fiasp® Japan sub
Slide 15: Financial results – First three months of 2018
Conference call First three months of 2018 Slide 15 Financial results – First three months of 2018 DKK million Change Change Q1 2018 Q1 2017 (reported DKK) (local currency) Sales 26,930 28,452 (5%) 5% Gross profit 22,733 24,201 (6%) Gross margin 84.4% 85.1% Sales and distribution costs (6,451) (6,78
Slide 16: Unfavourable currency impact in Q1 2018 driven by hedged and unhedged currencies
Conference call First three months of 2018 Slide 16 Unfavourable currency impact in Q1 2018 driven by development in both hedged and unhedged currencies USD/DKK CNY/DKK JPY/DKK GBP/DKK CAD/DKK 110 Hedged 2017 2018 Spot Impact of a Hedging Index (1 Jan 2017= 100) Currencies average average2 rate2 5%
Slide 17: Financial outlook for 2018
Conference call First three months of 2018 Slide 17 Financial outlook for 2018 Expectations Previous expectations 2 May 2018 1 Feb 2018 Sales growth - local currencies 3% to 5% 2% to 5% Sales growth - reported Around 6 percentage point lower Around 7 percentage points lower Operating profit growth -
Slide 18: Closing remarks
Conference call First three months of 2018 Slide 18 Closing remarks Solid leadership positions and continued market opportunities Promising pipeline and product launches 27% Novo Nordisk value market share in diabetes • The only company with a full portfolio of novel > > care and solid leadership po
Slide 19: Investor contact information
Conference call First three months of 2018 Slide 19 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York Sto